Trial · NCT03691727
Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
NCT03691727, Phase 1, Phase 2, Completed, David Hasan; results first posted 2021-10-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM). Trials, record NCT03691727. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03691727
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
- NCT number
- NCT03691727
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- David Hasan
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment
- First posted
- 2018-10-02
- Last updated
- 2022-01-10
- Results first posted
- 2021-10-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | Day 1 to Day 7 | The hypothesis is that the prevalence of intracranial hemorrhage (symptomatic and asymptomatic) secondary to ventriculostomy/VPS placement during the course of Aggrastat use is within 10% difference when compared to control using Day 1 and Day 7 non-contrast head CT to determine. |
| Primary | Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | Day 1 to Day 7 | The measurement of then incidence of delayed cerebral ischemia /clinical vasospasm in Tirofiban/Aggrastat group vs. placebo |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | Day 1 to Day 7 | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | Day 1 to Day 7 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | Tirofiban Hydrochloride (AGGRASTAT®) | 2 | Participants | ||
| Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | Standard of Care Control Arm | 1 | Participants | ||
| Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | Tirofiban Hydrochloride (AGGRASTAT®) | 1 | Participants | ||
| Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | Standard of Care Control Arm | 4 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tirofiban Hydrochloride (AGGRASTAT®) | 18 | |
| Overall Study | STARTED | Standard of Care Control Arm | 12 | |
| Overall Study | COMPLETED | Tirofiban Hydrochloride (AGGRASTAT®) | 16 | |
| Overall Study | COMPLETED | Standard of Care Control Arm | 11 | |
| Overall Study | NOT COMPLETED | Tirofiban Hydrochloride (AGGRASTAT®) | 2 | |
| Overall Study | NOT COMPLETED | Standard of Care Control Arm | 1 |
Source ClinicalTrials.gov
Adverse events150
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Tirofiban Hydrochloride (AGGRASTAT®) | 0 | 18 | |
| other | Abdominal Pain | Gastrointestinal disorders | Standard of Care Control Arm | 1 | 12 | |
| other | Bradycardia | Cardiac disorders | Tirofiban Hydrochloride (AGGRASTAT®) | 1 | 18 | |
| other | Bradycardia | Cardiac disorders | Standard of Care Control Arm | 1 | 12 | |
| other | External Ventricular Drain Malfunction | Product Issues | Tirofiban Hydrochloride (AGGRASTAT®) | 1 | 18 | |
| other | External Ventricular Drain Malfunction | Product Issues | Standard of Care Control Arm | 0 | 12 | |
| other | Fever | Infections and infestations | Tirofiban Hydrochloride (AGGRASTAT®) | 13 | 18 | |
| other | Fever | Infections and infestations | Standard of Care Control Arm | 9 | 12 | |
| other | Headache | Nervous system disorders | Tirofiban Hydrochloride (AGGRASTAT®) | 4 | 18 | |
| other | Headache | Nervous system disorders | Standard of Care Control Arm | 1 | 12 |
1 to 10 of 150Source ClinicalTrials.gov
See all 150 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tirofiban Hydrochloride (AGGRASTAT®) | 1 | 18 |
| Total, all-cause mortality | Standard of Care Control Arm | 0 | 12 |
| Total, other adverse events | Tirofiban Hydrochloride (AGGRASTAT®) | 18 | 18 |
| Total, other adverse events | Standard of Care Control Arm | 12 | 12 |
| Total, serious adverse events | Tirofiban Hydrochloride (AGGRASTAT®) | 18 | 18 |
| Total, serious adverse events | Standard of Care Control Arm | 12 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34470496 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: deaths from any cause | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03691727
GET https://conductscience.org/api/trials/v1/NCT03691727/events?page=2